SCHEDULE: BlackRock Holds 10% Stake in BioMarin Pharmaceutical

BlackRock, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 10.0% of BioMarin Pharmaceutical Inc.'s common stock as of October 31, 2026.

Summary

• BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting its beneficial ownership of BioMarin Pharmaceutical Inc. common stock.
• As of October 31, 2026, BlackRock beneficially owns 19,373,309 shares, representing 10.0% of the class.
• The filing details BlackRock's sole voting power at 18,549,911 shares and sole dispositive power for 19,373,309 shares.
• This filing is an amendment, indicating a continuation of BlackRock's reporting obligations.
• BlackRock's reporting business units are located in Delaware, and the principal business office is at 50 Hudson Yards, New York, NY 10001.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant institutional investor's continued stake and voting power, without immediate strategic shifts.

Positives

• BlackRock, a major institutional investor, maintains a significant 10.0% stake in BioMarin Pharmaceutical Inc.
• The filing confirms BlackRock's substantial voting and dispositive power over these shares, suggesting continued confidence or strategic interest.

Negatives

• No new negative information is presented; this is a routine disclosure of existing holdings.

Risks

• The filing does not explicitly mention new risks, but the concentration of ownership by a single large entity could be a factor in market dynamics.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from BioMarin Pharmaceutical Inc. It is a disclosure of BlackRock's current ownership status.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates."
• "It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release."
• "Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the common stock of BIOMARIN PHARMACEUTICAL INC. No one person's interest in the common stock of BIOMARIN PHARMACEUTICAL INC is more than five percent of the total outstanding common shares."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that large institutional holdings, as disclosed in Schedule 13G filings, are common in the biotechnology and pharmaceutical sectors. BioMarin Pharmaceutical Inc. operates in a highly competitive and R&D-intensive industry, where significant stakes held by major asset managers like BlackRock can influence market perception and corporate governance.

Stakeholder Impact

• Shareholders: The continued significant holding by BlackRock may provide a degree of stability and confidence in the company's stock, though it does not represent a change in control.
• Management: The filing confirms that BlackRock is not seeking to influence control of the issuer, as per their certification.

Next Steps

• BlackRock will continue to file amendments to Schedule 13G as required by regulatory rules, reflecting any changes in its beneficial ownership of BioMarin Pharmaceutical Inc. common stock.
• The company's attorneys-in-fact will continue to execute and file necessary documents to comply with reporting requirements.

Key Dates

Keywords

BioMarin Pharmaceutical, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Ownership Stake